Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) SVP Samantha Pearce sold 531 shares of the firm’s stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $155.00, for a total value of $82,305.00. Following the completion of the sale, the senior vice president now owns 11,309 shares in the company, valued at $1,752,895. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Samantha Pearce also recently made the following trade(s):
- On Tuesday, July 12th, Samantha Pearce sold 532 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $155.00, for a total transaction of $82,460.00.
- On Monday, June 27th, Samantha Pearce sold 8,508 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $155.00, for a total transaction of $1,318,740.00.
- On Wednesday, June 8th, Samantha Pearce sold 8,487 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $155.00, for a total value of $1,315,485.00.
Jazz Pharmaceuticals Price Performance
Ad Investing Daily
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Shares of NASDAQ JAZZ traded up $0.39 during mid-day trading on Monday, reaching $154.11. The company had a trading volume of 815,628 shares, compared to its average volume of 572,711. Jazz Pharmaceuticals plc has a twelve month low of $117.64 and a twelve month high of $169.98. The company has a current ratio of 3.67, a quick ratio of 2.45 and a debt-to-equity ratio of 1.87. The stock’s 50 day moving average is $153.10 and its 200-day moving average is $151.80.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $174.00 to $187.00 and gave the company an “equal weight” rating in a research note on Thursday. UBS Group reduced their price objective on shares of Jazz Pharmaceuticals from $194.00 to $191.00 and set a “buy” rating for the company in a report on Thursday. StockNews.com cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 2nd. Cowen boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. Finally, BMO Capital Markets increased their price objective on shares of Jazz Pharmaceuticals from $185.00 to $188.00 and gave the company an “outperform” rating in a report on Thursday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $203.69.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 638.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,310,729 shares of the specialty pharmaceutical company’s stock valued at $166,987,000 after buying an additional 1,133,121 shares during the last quarter. Deep Track Capital LP bought a new stake in Jazz Pharmaceuticals in the fourth quarter worth approximately $63,700,000. Millennium Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $56,159,000. JPMorgan Chase & Co. raised its holdings in shares of Jazz Pharmaceuticals by 11.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,221,792 shares of the specialty pharmaceutical company’s stock valued at $410,457,000 after purchasing an additional 325,479 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its stake in shares of Jazz Pharmaceuticals by 47.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 750,000 shares of the specialty pharmaceutical company’s stock valued at $95,550,000 after purchasing an additional 242,606 shares during the last quarter. 93.23% of the stock is owned by institutional investors and hedge funds.
About Jazz Pharmaceuticals
(Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Jazz Pharmaceuticals wasn’t on the list.
While Jazz Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Be the first to comment